| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 29,437 | -16,926 |
| Payment of loan payable | 0 | - |
| Proceeds from exercise of options | 453 | 453 |
| Proceeds from debt financings | 0 | - |
| Financing costs paid | 0 | - |
| Purchase of treasury stock | 91,240 | 12,998 |
| Net cash (used in) provided by financing activities | -90,787 | -12,545 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -105,782 | -50,750 |
| Cash and cash equivalents at beginning of period | 181,192 | - |
| Cash and cash equivalents at end of period | 75,410 | - |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)